Tufts: CROs investing more in tech, beating sponsors on site-related timelines

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/YiuCheung)
(Image: Getty/YiuCheung)

Related tags: Investment

Technology investments are catalyzing the study start-up process – and with more investment coming in from CROs, sponsors complete all site-related activity 6 to 11 weeks slower, according to a recent Tufts report.

The study start-up process averages 5 to 6 months in duration, though 11% of sites are never activated, according to a report by the Tufts Center for the Study of Drug Development (CSDD)​, which surveyed pharmaceutical organizations, biotech companies, and contract research organizations (CROs) to assess start-up practices and performance.

The research was supported by a grant from goBalto, a San Francisco, CA-based developer of web-based clinical research solutions.

As stakeholders are increasingly aware that better study start-up processes are linked to shorter clinical timelines, the emphasis has been shifting in that direction​,” said Sujay Jadhav, goBalto CEO. “The increasing use of technology and impact on cycle time reductions is a very positive industry trend​.”

According to the report, 80% of respondents who invested in technology reported time savings – with CROs investing 10% more than sponsors. As such, the research found that CROs complete all site-related activities 6 to 11 weeks faster than sponsors.

However, 80% of respondents still indicated a need to improve tools and technology to enable more effective processes, with 30-40% of respondents reporting they are unsatisfied with their processes. Those who did report a high level of satisfaction with their processes have 57.5% shorter cycle times, according to the report.

Additionally, across sponsors and CROs, average cycle times are 9.9 weeks shorter (28%) at repeat sites than at new sites.

It’s difficult to understand why there is so much variation and why there are so many inefficiencies and delays in study start-up, this was the impetus behind this research​,” said Craig Morgan, head of marketing at goBalto.

Numerous factors can adversely impact study startup and its efficiency, in an industry plagued by rising development costs and increasing complexities​,” he told us.

Some of these challenges include complex protocols, protocol amendments​, competition for sites, contract negotiations, regulatory changes and investigator​ and CRA turnover​, among others.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars